10 recruiting. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 10 |
| Phase 1 | 2 | Recruiting 2 |
Follow Diffuse Large B Cell Lymphoma (DLBCL): new trials by email Literature Review of Diffuse Large B Cell Lymphoma (DLBCL) trials Research Report on Diffuse Large B Cell Lymphoma (DLBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor - Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2026-04-01 | 2026-04-15 |
| Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma Zanubrutinib+Pola-R-CHP - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 50 | 2025-11-20 | 2026-01-28 |
| Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma Anbal-cel - Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Hyungwoo Cho | 12 | 2025-11-12 | 2025-12-17 |
| A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 97 | 2025-07-30 | 2025-08-15 |
| Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9® - Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated | Phase 2 | Recruiting | Vastra Gotaland Region | 100 | 2025-05-12 | 2025-06-05 |
| Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) glofitamab - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2025-01-24 | 2026-04-24 |
| A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma Glofitamab, Polatuzumab, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 42 | 2025-01-16 | 2026-10-30 |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Sun Yat-sen University | 39 | 2024-11-01 | 2024-10-22 |
Lymphoma, Large B-Cell, Diffuse (10) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Papillomavirus Infections (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma (9) · Lymphoma, B-Cell (9) · Lymphoma, Non-Hodgkin (9) · Bone Marrow Diseases (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Disease Attributes (1) · Genital Diseases (1)
Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (2) · Rituximab (2) · glofitamab (2) · polatuzumab vedotin (2) · Filgrastim (1) · Gemcitabine (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · Oxaliplatin (1) · R-CHOP protocol (1) · Sirolimus (1) · obinutuzumab (1) · orelabrutinib (1) · pegfilgrastim (1)
Beijing Tongren Hospital (2) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Hyungwoo Cho (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · Sun Yat-sen University (1) · Umoja Biopharma (1) · University Health Network, Toronto (1) · Vastra Gotaland Region (1)
China (4) · United States (3) · Canada (1) · South Korea (1) · Sweden (1)
Hyungwoo Cho, Ph.D (1) · John Kuruvilla, FRCPC (1) · Liang Wang, M.D. (1) · Luke Walker, MD (1) · Nirav Shah, MD (1) · Pallawi Torka, MD (1)